S. Russell, K. Peng, and J. Bell, Oncolytic virotherapy, Nature Biotechnology, vol.311, issue.7, pp.658-670, 2012.
DOI : 10.1038/nbt.2287

E. Galanis, P. Atherton, and M. Maurer, Oncolytic Measles Virus Expressing the Sodium Iodide Symporter to Treat Drug-Resistant Ovarian Cancer, Cancer Research, vol.75, issue.1, pp.22-30, 2015.
DOI : 10.1158/0008-5472.CAN-14-2533

E. Galanis, L. Hartmann, and W. Cliby, Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer, Cancer Research, vol.70, issue.3, pp.875-882, 2010.
DOI : 10.1158/0008-5472.CAN-09-2762

K. Porpodis, P. Zarogoulidis, and E. Boutsikou, Malignant pleural mesothelioma: current and future perspectives, J Thorac Dis, vol.5, pp.397-406, 2013.

O. Roe and G. Stella, Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic, European Respiratory Review, vol.24, issue.135, pp.115-131, 2015.
DOI : 10.1183/09059180.00007014

A. Husain, T. Colby, and N. Ordonez, Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2012 Update of the Consensus Statement from the International Mesothelioma Interest Group, Archives of Pathology & Laboratory Medicine, vol.137, issue.5, pp.647-667, 2013.
DOI : 10.5858/arpa.2012-0214-OA

A. Scherpereel, P. Astoul, and P. Baas, Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma, European Respiratory Journal, vol.35, issue.3, pp.479-495, 2010.
DOI : 10.1183/09031936.00063109

N. Senzer, H. Kaufman, and T. Amatruda, Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor???Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma, Journal of Clinical Oncology, vol.27, issue.34, pp.5763-5771, 2009.
DOI : 10.1200/JCO.2009.24.3675

J. Kucharczuk, B. Randazzo, and M. Chang, Use of a " replicationrestricted " herpes virus to treat experimental human malignant mesothelioma, Cancer Res, vol.57, issue.3, pp.466-471, 1997.

P. Adusumilli, M. Chan, and Y. Chun, Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma, Cancer Biology & Therapy, vol.5, issue.1, pp.48-53, 2006.
DOI : 10.4161/cbt.5.1.2237

P. Adusumilli, M. Chan, and M. Hezel, Radiation-Induced Cellular DNA Damage Repair Response Enhances Viral Gene Therapy Efficacy in the Treatment of Malignant Pleural Mesothelioma, Annals of Surgical Oncology, vol.102, issue.4 Suppl, pp.258-269, 2007.
DOI : 10.1245/s10434-006-9127-4

P. Adusumilli, D. Eisenberg, and B. Stiles, Intraoperative localization of lymph node metastases with a replication-competent herpes simplex virus, The Journal of Thoracic and Cardiovascular Surgery, vol.132, issue.5, pp.1179-1188, 2006.
DOI : 10.1016/j.jtcvs.2006.07.005

P. Adusumilli, B. Stiles, and M. Chan, Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses, The Journal of Gene Medicine, vol.158, issue.5, pp.603-615, 2006.
DOI : 10.1002/jgm.877

P. Adusumilli, D. Eisenberg, and Y. Chun, Virally Directed Fluorescent Imaging Improves Diagnostic Sensitivity in the Detection of Minimal Residual Disease After Potentially Curative Cytoreductive Surgery, Journal of Gastrointestinal Surgery, vol.9, issue.8, pp.1138-1146, 2005.
DOI : 10.1016/j.gassur.2005.06.029

J. Heo, T. Reid, and L. Ruo, Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer, Nature Medicine, vol.53, issue.3, pp.329-336, 2013.
DOI : 10.1038/nm.3089

C. Breitbach, J. Burke, and D. Jonker, Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans, Nature, vol.183, issue.7362, pp.99-102, 2011.
DOI : 10.1038/nature10358

L. Belin, J. Ady, and C. Lewis, An oncolytic vaccinia virus expressing the human sodium iodine symporter prolongs survival and facilitates SPECT/CT imaging in an orthotopic model of malignant pleural mesothelioma, Surgery, vol.154, issue.3, pp.486-495, 2013.
DOI : 10.1016/j.surg.2013.06.004

P. Brader, K. Kelly, and N. Chen, Imaging a Genetically Engineered Oncolytic Vaccinia Virus (GLV-1h99) Using a Human Norepinephrine Transporter Reporter Gene, Clinical Cancer Research, vol.15, issue.11, pp.3791-3801, 2009.
DOI : 10.1158/1078-0432.CCR-08-3236

K. Kelly, Y. Woo, and P. Brader, Novel Oncolytic Agent GLV-1h68 Is Effective Against Malignant Pleural Mesothelioma, Human Gene Therapy, vol.19, issue.8, pp.774-782, 2008.
DOI : 10.1089/hum.2008.036
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940611

S. Acuna, K. Ottolino-perry, B. Cako, N. Tang, F. Angarita et al., Oncolytic Vaccinia Virus as an Adjuvant Treatment to Cytoreductive Surgery for Malignant Peritoneal Mesothelioma, Annals of Surgical Oncology, vol.18, issue.2, pp.2259-2266, 2014.
DOI : 10.1245/s10434-014-3651-4

S. Mukherjee, T. Haenel, and R. Himbeck, Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: Persistent transgene expression despite antibody generation, Cancer Gene Therapy, vol.7, issue.5, pp.663-670, 2000.
DOI : 10.1038/sj.cgt.7700133

K. Garber, China Approves World's First Oncolytic Virus Therapy For Cancer Treatment, JNCI Journal of the National Cancer Institute, vol.98, issue.5, pp.298-300, 2006.
DOI : 10.1093/jnci/djj111

Z. Zhu, S. Makhija, and B. Lu, Targeting Mesothelioma Using an Infectivity Enhanced Survivin-Conditionally Replicative Adenoviruses, Journal of Thoracic Oncology, vol.1, issue.7, pp.701-711, 2006.
DOI : 10.1016/S1556-0864(15)30385-3

T. Fukazawa, J. Matsuoka, Y. Naomoto, Y. Maeda, M. Durbin et al., Malignant Pleural Mesothelioma-Targeted CREBBP/EP300 Inhibitory Protein 1 Promoter System for Gene Therapy and Virotherapy, Cancer Research, vol.68, issue.17, pp.7120-7129, 2008.
DOI : 10.1158/0008-5472.CAN-08-0047

Y. Watanabe, T. Kojima, and S. Kagawa, A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy, Oncogene, vol.61, issue.8, pp.1145-1154, 2010.
DOI : 10.1093/jnci/92.8.636

A. Gotoh, T. Kanno, and H. Nagaya, Gene therapy using adenovirus against malignant mesothelioma, Anticancer Res, vol.32, issue.9, pp.3743-3747, 2012.

S. Kubo, Y. Kawasaki, and N. Yamaoka, Complete regression of human malignant mesothelioma xenografts following local injection of midkine promoter-driven oncolytic adenovirus, The Journal of Gene Medicine, vol.68, issue.8, pp.681-692, 2010.
DOI : 10.1002/jgm.1486

M. Takagi-kimura, T. Yamano, and A. Tamamoto, Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma, Cancer Science, vol.128, issue.11, pp.1433-1439, 2013.
DOI : 10.1111/cas.12267

Y. Tsuruta, L. Pereboeva, and M. Breidenbach, A Fiber-Modified Mesothelin Promoter-Based Conditionally Replicating Adenovirus for Treatment of Ovarian Cancer, Clinical Cancer Research, vol.14, issue.11, pp.3582-3588, 2008.
DOI : 10.1158/1078-0432.CCR-07-5053

M. Yamanaka, Y. Tada, and K. Kawamura, E1B-55 kDa-Defective Adenoviruses Activate p53 in Mesothelioma and Enhance Cytotoxicity of Anticancer Agents, Journal of Thoracic Oncology, vol.7, issue.12, pp.1850-1857, 2012.
DOI : 10.1097/JTO.0b013e3182725fa4

Q. Li, K. Kawamura, and M. Yamanaka, Upregulated p53 expression activates apoptotic pathways in wild-type p53-bearing mesothelioma and enhances cytotoxicity of cisplatin and pemetrexed, Cancer Gene Therapy, vol.7, issue.3, pp.218-228, 2012.
DOI : 10.1158/1078-0432.CCR-05-0405

S. Frizelle, J. Grim, and J. Zhou, Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression, Oncogene, vol.16, issue.24, pp.3087-3095, 1998.
DOI : 10.1038/sj.onc.1201870

C. Yang, L. You, and C. Yeh, Adenovirus-Mediated p14ARF Gene Transfer in Human Mesothelioma Cells, JNCI Journal of the National Cancer Institute, vol.92, issue.8, pp.636-641, 2000.
DOI : 10.1093/jnci/92.8.636

D. Sterman, A. Haas, and E. Moon, A Trial of Intrapleural Adenoviral-mediated Interferon-??2b Gene Transfer for Malignant Pleural Mesothelioma, American Journal of Respiratory and Critical Care Medicine, vol.184, issue.12, pp.1395-1399, 2011.
DOI : 10.1164/rccm.201103-0554CR

D. Sterman, A. Recio, and R. Carroll, A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses, Clin Cancer Res, vol.1315, issue.1, pp.4456-4466, 2007.

D. Sterman, A. Recio, and A. Haas, A Phase I Trial of Repeated Intrapleural Adenoviral-mediated Interferon-?? Gene Transfer for Mesothelioma and Metastatic Pleural Effusions, Molecular Therapy, vol.18, issue.4, pp.852-860, 2010.
DOI : 10.1038/mt.2009.309

M. Tagawa, Y. Tada, H. Shimada, and K. Hiroshima, Gene therapy for malignant mesothelioma: Current prospects and challenges, Cancer Gene Therapy, vol.13, issue.3, pp.150-156, 2013.
DOI : 10.1038/sj.cgt.7700133

C. Willmon, V. Saloura, and Z. Fridlender, Expression of IFN-?? Enhances Both Efficacy and Safety of Oncolytic Vesicular Stomatitis Virus for Therapy of Mesothelioma, Cancer Research, vol.69, issue.19, pp.7713-7720, 2009.
DOI : 10.1158/0008-5472.CAN-09-1013

V. Saloura, L. Wang, and Z. Fridlender, Evaluation of an Attenuated Vesicular Stomatitis Virus Vector Expressing Interferon-?? for Use in Malignant Pleural Mesothelioma: Heterogeneity in Interferon Responsiveness Defines Potential Efficacy, Human Gene Therapy, vol.21, issue.1, pp.51-64, 2010.
DOI : 10.1089/hum.2009.088

A. Gauvrit, S. Brandler, C. Sapede-peroz, N. Boisgerault, F. Tangy et al., Measles Virus Induces Oncolysis of Mesothelioma Cells and Allows Dendritic Cells to Cross-Prime Tumor-Specific CD8 Response, Cancer Research, vol.68, issue.12, pp.4882-4892, 2008.
DOI : 10.1158/0008-5472.CAN-07-6265
URL : https://hal.archives-ouvertes.fr/pasteur-00330770

H. Li, K. Peng, D. Dingli, R. Kratzke, and S. Russell, Oncolytic measles viruses encoding interferon ?? and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy, Cancer Gene Therapy, vol.60, issue.8, pp.550-558, 2010.
DOI : 10.1038/sj.gt.3301787

L. Phuong, C. Allen, and K. Peng, Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme, Cancer Res, vol.63, issue.10, pp.2462-2469, 2003.

R. Myers, S. Greiner, and M. Harvey, Preclinical Pharmacology and Toxicology of Intravenous MV-NIS, an Oncolytic Measles Virus Administered With or Without Cyclophosphamide, Clinical Pharmacology & Therapeutics, vol.125, issue.6, pp.700-710, 2007.
DOI : 10.1038/sj.clpt.6100409

S. Lapp, V. Pfankuche, W. Baumgartner, and C. Puff, Viral Oncolysis ??? Can Insights from Measles Be Transferred to Canine Distemper Virus?, Viruses, vol.6, issue.6, pp.2340-2375, 2014.
DOI : 10.3390/v6062340
URL : http://doi.org/10.3390/v6062340

Y. Morodomi, T. Yano, and H. Kinoh, BioKnife, a uPA Activity-dependent Oncolytic Sendai Virus, Eliminates Pleural Spread of Malignant Mesothelioma via Simultaneous Stimulation of uPA Expression, Molecular Therapy, vol.20, issue.4, pp.769-777, 2012.
DOI : 10.1038/mt.2011.305

G. Silberhumer, P. Brader, and J. Wong, Genetically Engineered Oncolytic Newcastle Disease Virus Effectively Induces Sustained Remission of Malignant Pleural Mesothelioma, Molecular Cancer Therapeutics, vol.9, issue.10, pp.2761-2769, 2010.
DOI : 10.1158/1535-7163.MCT-10-0090
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3266818

E. Galanis, S. Markovic, and V. Suman, Phase II Trial of Intravenous Administration of Reolysin?? (Reovirus Serotype-3-dearing Strain) in Patients with Metastatic Melanoma, Molecular Therapy, vol.20, issue.10, pp.1998-2003, 2012.
DOI : 10.1038/mt.2012.146

C. Comins, J. Spicer, and A. Protheroe, REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer, Clinical Cancer Research, vol.16, issue.22, pp.5564-5572, 2010.
DOI : 10.1158/1078-0432.CCR-10-1233

Y. Kawasaki, A. Tamamoto, and M. Takagi-kimura, Replication-competent retrovirus vector-mediated prodrug activator gene therapy in experimental models of human malignant mesothelioma, Cancer Gene Therapy, vol.37, issue.8, pp.571-578, 2011.
DOI : 10.1158/1078-0432.CCR-06-1452

S. Kubo, M. Takagi-kimura, C. Logg, and N. Kasahara, Highly efficient tumor transduction and antitumor efficacy in experimental human malignant mesothelioma using replicating gibbon ape leukemia virus, Cancer Gene Therapy, vol.37, issue.12, pp.671-677, 2013.
DOI : 10.1128/JVI.76.24.12783-12791.2002

C. Breitbach, R. Arulanandam, D. Silva, and N. , Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans, Cancer Research, vol.73, issue.4, pp.1265-1275, 2013.
DOI : 10.1158/0008-5472.CAN-12-2687

C. Breitbach, D. Silva, N. Falls, and T. , Targeting Tumor Vasculature With an Oncolytic Virus, Molecular Therapy, vol.19, issue.5, pp.886-894, 2011.
DOI : 10.1038/mt.2011.26

N. Elsedawy and S. Russell, Oncolytic vaccines, Expert Review of Vaccines, vol.12, issue.10, pp.1155-1172, 2013.
DOI : 10.1586/14760584.2013.836912

V. Cerullo, S. Pesonen, and I. Diaconu, Oncolytic Adenovirus Coding for Granulocyte Macrophage Colony-Stimulating Factor Induces Antitumoral Immunity in Cancer Patients, Cancer Research, vol.70, issue.11, pp.4297-4309, 2010.
DOI : 10.1158/0008-5472.CAN-09-3567

D. Sterman, A. Recio, and A. Vachani, Long-term Follow-up of Patients with Malignant Pleural Mesothelioma Receiving High-Dose Adenovirus Herpes Simplex Thymidine Kinase/Ganciclovir Suicide Gene Therapy, Clinical Cancer Research, vol.11, issue.20, pp.7444-7453, 2005.
DOI : 10.1158/1078-0432.CCR-05-0405

T. Gajewski and L. Corrales, New perspectives on type I IFNs in cancer, Cytokine & Growth Factor Reviews, vol.26, issue.2, pp.175-178, 2015.
DOI : 10.1016/j.cytogfr.2015.01.001

C. Willmon, R. Diaz, and P. Wongthida, Vesicular Stomatitis Virus-induced Immune Suppressor Cells Generate Antagonism Between Intratumoral Oncolytic Virus and Cyclophosphamide, Molecular Therapy, vol.19, issue.1, pp.140-149, 2011.
DOI : 10.1038/mt.2010.224

H. Inoue and T. K. , Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments, Cell Death and Differentiation, vol.17, issue.1, pp.39-49, 2014.
DOI : 10.1038/cdd.2013.84

C. Achard, N. Boisgerault, T. Delaunay, F. Tangy, M. Gregoire et al., Induction of immunogenic tumor cell death by attenuated oncolytic measles virus, J Clin Cell Immunol, vol.6, issue.1, p.291, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01148993

J. Guillerme, N. Boisgerault, and D. Roulois, Measles Virus Vaccine-Infected Tumor Cells Induce Tumor Antigen Cross-Presentation by Human Plasmacytoid Dendritic Cells, Clinical Cancer Research, vol.19, issue.5, pp.1147-1158, 2013.
DOI : 10.1158/1078-0432.CCR-12-2733

J. Fonteneau, J. Guillerme, F. Tangy, and M. Gregoire, Attenuated measles virus used as an oncolytic virus activates myeloid and plasmacytoid dendritic cells, OncoImmunology, vol.2, issue.5, p.24212, 2013.
DOI : 10.1089/jir.2011.0077

J. Tel and I. De-vries, Potential applications for plasmacytoid dendritic cells in cancer immunotherapy, Immunotherapy, vol.4, issue.10, pp.979-982, 2012.
DOI : 10.2217/imt.12.115

S. Russell, M. Federspiel, and K. Peng, Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy, Mayo Clinic Proceedings, vol.89, issue.7, pp.926-933, 2014.
DOI : 10.1016/j.mayocp.2014.04.003

C. Engeland, C. Grossardt, and R. Veinalde, CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy, Molecular Therapy, vol.22, issue.11, pp.1949-1959, 2014.
DOI : 10.1038/mt.2014.160
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429737

T. Ranki, T. Joensuu, and E. Jäger, lymphocytes and Th1 type polarization, OncoImmunology, vol.34, issue.10, p.958937, 2014.
DOI : 10.1007/s00262-011-1172-6

K. Rajani, V. Alonso-camino, N. Boisgerault, and R. Vile, Viral platforms for expression of tumor antigens in cancer immunotherapy, Tumor Immunology and Immunotherapy, pp.217-234
DOI : 10.1093/med/9780199676866.003.0015

F. Guillot, B. Boutin, and C. Blanquart, Vaccination with epigenetically treated mesothelioma cells induces immunisation and blocks tumour growth, Vaccine, vol.29, issue.33, pp.5534-5543, 2011.
DOI : 10.1016/j.vaccine.2011.05.029

S. Leclercq, F. Gueugnon, and B. Boutin, A 5-aza-2'-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma, European Respiratory Journal, vol.38, issue.5, pp.1105-1116, 2011.
DOI : 10.1183/09031936.00081310

T. Nguyên, H. Abdelbary, and M. Arguello, Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis, Proceedings of the National Academy of Sciences, vol.105, issue.39, pp.14981-14986, 2008.
DOI : 10.1073/pnas.0803988105

A. Otsuki, A. Patel, and K. Kasai, Histone Deacetylase Inhibitors Augment Antitumor Efficacy of Herpes-based Oncolytic Viruses, Molecular Therapy, vol.16, issue.9, pp.1546-1555, 2008.
DOI : 10.1038/mt.2008.155

T. Nguyen, M. Wilson, and J. Hiscott, Oncolytic viruses and histone deacetylase inhibitors???A multi-pronged strategy to target tumor cells, Cytokine & Growth Factor Reviews, vol.21, issue.2-3, pp.2-3153, 2010.
DOI : 10.1016/j.cytogfr.2010.03.002

N. Forbes, H. Abdelbary, M. Lupien, J. Bell, and J. Diallo, Exploiting tumor epigenetics to improve oncolytic virotherapy, Frontiers in Genetics, vol.4, p.184, 2013.
DOI : 10.3389/fgene.2013.00184